AbbVie is gaining investor confidence as its new immunology drugs Skyrizi and Rinvoq show strong revenue growth, offsetting declines from older products like Humira. The company raised its full-year earnings forecast after beating revenue expectations, supported by a robust pipeline and significant R&D investments. Despite risks from patent expirations and past financial leverage, AbbVie’s consistent dividend increases and strong margins make it a compelling long-term investment. Recent market volatility offers buying opportunities for investors focused on steady income and growth potential.
BOTOX Cosmetic, under Allergan Aesthetics and AbbVie, announced 250 women entrepreneurs chosen for The Confidence Collective program, offering skill-building, mentorship, and networking. From this group, 20 participants will receive $20,000 grants to...
Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, sho...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eigh...
Following AbbVie's pending acquisition of Apogee Therapeutics, big pharma is actively seeking clinical-stage biotech firms with late-stage data and strategic fit in immunology, obesity, or oncology. Among Nasdaq-listed biotechs, Syndax Pharmaceutical...
